All Boards >> Irritable Bowel Syndrome Research Library

HeatherAdministrator

Reged: 12/09/02
Posts: 7687
Loc: Seattle, WA
Rifaximin vs Placebo in Reducing Symptoms in Adults With IBS
11/26/06 02:39 PM

Efficacy of Rifaximin vs Placebo in Reducing Symptoms in Adults With IBS


David A. Johnson, MD, FACG, FACP

The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome: A Randomized Trial
Pimentel M, Park S, Mirocha J, Kane SV, Kong Y

Ann Intern Med. 2006;145:557-563

Summary
Irritable bowel syndrome (IBS) is a prevalent condition that has been labeled as a "functional bowel disorder." By this delineation, its cause has been thought to be indefinable. The primary symptoms of this disorder include constipation, diarrhea, abdominal bloating, and cramping. Recent attention has focused on a potential infectious component of IBS.

In this study, Pimental and colleagues investigated the use of rifaximin in patients diagnosed with IBS as defined by the Rome I criteria. Rifaximin is a nonabsorbable, gut-selective antibiotic derived from the rifamycin family that may reduce bacterial overgrowth due to its broad-spectrum activity in vitro against gram-positive, gram-negative, aerobic, anaerobic, and microaerophilic bacteria.

This was a prospective, double-blind randomized controlled trial that involved 43 patients who received 400 mg of rifaximin 3-times daily and 44 who received placebo for 10 days. Patient symptom and stool diaries were completed prior to entry, during the study, and the week following treatment.

Global improvement was found to vary widely across weeks for most patients, and the data were reported as an averaging of the symptoms over all 10 weeks of the study. This percentage was significant as a function of group (P = .020), but not as a function of week (P = .78) or group-by-week (P = .96). The patients in the rifaximin group had a 36.4% improvement in global symptoms compared with 21.0% for the placebo group.

The rifaximin group also reported significantly less bloating on a visual analog scale compared with the placebo group (P = .010), a difference that persisted after controlling for differences between groups in baseline pain scores (P = .001). Besides bloating, none of the secondary endpoints improved with treatment compared with placebo on the visual analog scale: abdominal pain (P = .32), diarrhea (P = .67), and constipation (P = .069).

Viewpoint
Rifaximin is currently US Food and Drug Administration-approved for the treatment of traveler's diarrhea, although these study findings suggest a more expanded potential role for this antibiotic. However, before recommending widespread globalized use of this medication for all patients with IBS, healthcare providers should be aware of several limitations of this study. First, although this was a "multicenter study," there was a considerable imbalance between enrollment from the 2 study sites (83 participants vs 3 participants). Second, because the global measure includes pain, it is important to note that there was an imbalance in baseline pain scores between the 2 patient groups at entry. The imbalance (higher baseline pain scores in the rifaximin group) potentially favors the reduction in the global scores. Additionally, this primary outcome measure is unique in the spectrum of the recent treatment intervention evaluations for IBS trials, and therefore makes comparisons with other trials somewhat difficult. Third, the study authors relied solely on the use of the lactose breath test to define small bowel bacterial overgrowth. Future tests in this area should evaluate the use of other breath tests to define bacterial overgrowth in the small intestine. Fourth, the data suggest that rifaximin may be of more help in the subset of patients with bloating. In IBS, abdominal bloating is reported in more than 50% of patients, and a recent study suggests that changes in abdominal girth can reach 12 cm in more than 50% of patients.[1]

Clearly, this study highlights a new concept in the potential pathogenesis of IBS. An infectious cause may offer a tremendous opportunity to manage an otherwise somewhat frustrating disease -- both for patients and their treating physicians.

Abstract

References
Houghton LA, Lea R, Agrawal A, Reilly B, Whorwell PJ. Relationship of abdominal bloating to distention in irritable bowel syndrome and effect of bowel habit. Gastroenterology. 2006;131:1003-1010.


David A. Johnson, MD, FACG, FACP, Professor of Medicine, Chief of Gastroenterology, Eastern Virginia School of Medicine, Norfolk, Virginia


David A. Johnson, MD, FACG, FACP, has disclosed that he has received grants for clinical research from AstraZeneca, TAP, Wyeth, Novartis, and Abbott, and grants for educational activities from AstraZeneca and Novartis. Dr. Johnson has also disclosed that he has served as an advisor or consultant to AstraZeneca, TAP, and Novartis.


Medscape Gastroenterology. 2006;8(2) 2006 Medscape

http://www.medscape.com/viewarticle/547055?src=mp

--------------------
Heather is the Administrator of the IBS Message Boards. Shes the author of Eating for IBS and The First Year: IBS, and the CEO of Heather's Tummy Care. Join her IBS Newsletter. Meet Heather on Facebook!

Post Extras Print Post Remind Me! Notify Moderator

Entire thread
Subject Posted by Posted on
* Pharmaceutical HeatherAdministrator 07/14/03 01:50 PM
. * Long-term cannabis use increases risk for IBS HeatherAdministrator 10/19/17 04:04 PM
. * FDA approves new drug for chronic constipation HeatherAdministrator 01/26/17 03:05 PM
. * Mixed Opioid Agent Adds to Growing List of Therapies for IBS-D HeatherAdministrator 01/27/16 02:48 PM
. * Low-dose naltreoxone for the treatment of irritable bowel syndrome HeatherAdministrator 01/26/16 01:20 PM
. * Amitiza benefited patients with chronic idiopathic constipation HeatherAdministrator 02/10/15 04:15 PM
. * Medical Marijuana for Digestive Disorders: High Time to Prescribe? HeatherAdministrator 09/17/14 02:08 PM
. * Antibiotics Early in Life May Boost Obesity Risk HeatherAdministrator 08/18/14 03:13 PM
. * Antidepressants, psychological therapies effectively treated IBS HeatherAdministrator 07/15/14 02:49 PM
. * Proton pump inhibitor (acid reflux drugs) may cause heart disease HeatherAdministrator 09/23/13 03:22 PM
. * Older drugs are better than new ones HeatherAdministrator 06/13/13 02:00 PM
. * On Anti-Depressants? Some Raise Risk of C. Diff Infection HeatherAdministrator 05/13/13 05:51 PM
. * Heartburn drugs, NSAID painkillers use linked to IBS symptoms HeatherAdministrator 03/18/13 01:24 PM
. * FDA approves Linzess to treat certain cases of irritable bowel syndrome and constipation HeatherAdministrator 08/31/12 11:25 AM
. * 3-month FDA delay for potential IBS drug linaclotide HeatherAdministrator 04/23/12 01:45 PM
. * Latest FDA watch list includes GI drugs HeatherAdministrator 04/23/12 01:42 PM
. * Antibiotics that reduce gut bacteria linked to obesity HeatherAdministrator 05/06/11 12:25 PM
. * Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases HeatherAdministrator 02/10/11 10:23 AM
. * Antacids increase risk of pneumonia HeatherAdministrator 01/14/11 04:35 PM
. * Editorial - Antibiotic Rifaximin (Xifaxan) Therapy for the Irritable Bowel Syndrome HeatherAdministrator 01/07/11 03:01 PM
. * Antiobiotic Rifaximin (Xifaxan) for Patients with Irritable Bowel Syndrome without Constipation HeatherAdministrator 01/07/11 02:59 PM
. * Proton Pump Inhibitor Drugs Tied to 80% Increase in Clostridium difficile Risk HeatherAdministrator 11/10/10 11:29 AM
. * Phase 3 clinical trials of linaclotide for IBS constipation HeatherAdministrator 10/13/10 02:44 PM
. * An over-the-counter drug for constipation offers superior symptom relief compared with a commonly used prescription agent HeatherAdministrator 07/16/10 03:17 PM
. * Benefit/risk ratio of Renzapride not sufficient to warrant further study in IBS-C HeatherAdministrator 04/07/10 01:32 PM
. * Adverse effects of drugs on small intestine and colon HeatherAdministrator 03/16/10 11:23 AM
. * Children's Belly Aches Don't Disappear With Antidepressant HeatherAdministrator 03/11/10 01:14 PM
. * Survey: Marijuana Use In Patients With IBS HeatherAdministrator 01/12/10 03:17 PM
. * FDA Approves Amitiza for IBS-C HeatherAdministrator 05/23/08 10:59 AM
. * Zelnorm no longer available except for emergency use HeatherAdministrator 04/11/08 12:05 PM
. * Clinical trial: phase 2 trial of lubiprostone for irritable bowel syndrome with constipation. HeatherAdministrator 02/15/08 11:20 AM
. * Role of Antibiotics vs Conventional Pharmacotherapy in Treating Symptoms of Irritable Bowel Syndrome HeatherAdministrator 01/03/08 04:45 PM
. * FDA permits the restricted use of Zelnorm HeatherAdministrator 08/09/07 11:41 AM
. * Antidepressant Therapy (Imipramine and Citalopram) for Irritable Bowel Syndrome HeatherAdministrator 06/20/07 01:56 PM
. * Neuromuscular Dysfunction and IBS: Clinical Implications for Drug Use HeatherAdministrator 02/04/07 04:30 PM
. * Enteric Bacteria and IBS HeatherAdministrator 11/26/06 02:51 PM
. * Rifaximin vs Placebo in Reducing Symptoms in Adults With IBS HeatherAdministrator 11/26/06 02:39 PM
. * Antibiotic Rifaximin Appears Safe and Effective for Irritable Bowel Syndrome HeatherAdministrator 10/26/06 10:29 AM
. * Citalopram (Celexa) Improves Symptoms of Irritable Bowel Syndrome HeatherAdministrator 10/14/06 12:57 PM
. * Marijuana eases chronic pain HeatherAdministrator 07/17/06 11:49 AM
. * Doctors group launches war on drug ads HeatherAdministrator 07/17/06 11:17 AM
. * New IBS drug in development in Japan HeatherAdministrator 07/05/06 05:13 PM
. * Marijuana and the gastrointestinal tract HeatherAdministrator 06/12/06 03:38 PM
. * Zelnorm Rejected Again in Europe HeatherAdministrator 04/02/06 03:25 PM
. * Antidepressants for IBS HeatherAdministrator 03/16/06 12:31 PM
. * Takeda Laxative Wins U.S. Approval for Adults HeatherAdministrator 02/18/06 01:36 PM
. * Cilansetron: ; Solvay Pharmaceuticals suspends registration activites in the U.S., HeatherAdministrator 01/18/06 04:15 PM
. * Hearburn Drugs Cause Diarrhea HeatherAdministrator 01/08/06 05:10 PM
. * Zelnorm fails to win EU panel backing HeatherAdministrator 12/21/05 11:25 AM
. * Non-steroidal anti-inflammatory drugs and gastrointestinal damage HeatherAdministrator 12/08/05 12:51 PM
. * Octreotide May Be Effective in Treatment of Nonconstipated IBS HeatherAdministrator 12/08/05 12:31 PM
. * Lack of Lasting Effectiveness of Miralax Laxative Treatment of Constipation. HeatherAdministrator 08/07/05 04:18 PM
. * Acute Hepatitis Associated With Lotronex HeatherAdministrator 07/24/05 02:37 PM
. * FDA revisions to safety labeling for Lotronex (alosetron ) HeatherAdministrator 05/22/05 06:46 PM
. * Clinical pharmacology of new motility promoting agents HeatherAdministrator 05/22/05 06:33 PM
. * Rationale for Using Serotonergic Agents to Treat Irritable Bowel Syndrome HeatherAdministrator 05/08/05 06:21 PM
. * Zelnorm Associated With Rare Cases of Severe Diarrhea, Ischemic Colitis HeatherAdministrator 04/24/05 03:48 PM
. * Clinical Response to Tricyclic Antidepressants in Functional Bowel Disorders not Related to Dosage HeatherAdministrator 03/28/05 01:32 PM
. * Efficacy and Safety of Alosetron in Men with Diarrhea-Predominant IBS HeatherAdministrator 02/19/05 05:56 PM
. * Irritable Bowel Syndrome Medications Side Effects Survey HeatherAdministrator 11/09/04 02:04 PM
. * On the Relationship Between Colon Ischemia, Irritable Bowel Syndrome, and Serotonergic Therapy of Irritable Bowel Syndrome HeatherAdministrator 10/24/04 07:10 PM
. * New Risk Information on Zelnorm for IBS for Women HeatherAdministrator 07/11/04 02:18 PM
. * The Relationship among Previous Antimicrobial Use and H. Pylori Infections HeatherAdministrator 06/27/04 01:33 PM
. * Therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome HeatherAdministrator 06/04/04 03:54 PM
. * Pharmaceutical companies funding a number of studies into IBS in the UK HeatherAdministrator 05/25/04 12:00 PM
. * Irritable bowel syndrome helped by Paroxetine, a drug for depression HeatherAdministrator 05/10/04 02:15 PM
. * Fears cause low sales of Lotronex HeatherAdministrator 05/10/04 01:46 PM
. * Zelnorm Warning Issued by FDA HeatherAdministrator 05/10/04 01:01 PM
. * Renzapride Improves Symptoms in Constipation-Predominant Irritable Bowel Syndrome HeatherAdministrator 12/01/03 06:14 PM
. * Clinical Trial Guidelines for Pharmacological Treatment of IBS - Pharmacological Options HeatherAdministrator 12/01/03 05:55 PM
. * SOLVAY presses ahead with cilansetron, a new IBS drug HeatherAdministrator 11/18/03 03:43 PM
. * Measuring Treatment Effects in IBS Trials HeatherAdministrator 10/20/03 03:30 PM
. * FDA Orders Novartis To Pull Zelnorm Ads HeatherAdministrator 10/07/03 11:25 PM
. * Step-down dosage of PPI drugs for hearburn HeatherAdministrator 09/30/03 01:26 PM
. * Evaluation of drug treatment in irritable bowel syndrome HeatherAdministrator 09/30/03 12:52 PM
. * Pain Relievers and Intestinal Disorders HeatherAdministrator 09/16/03 04:20 PM
. * Hypersensitivity and hyperreactivity in IBS: opportunity for drug discovery HeatherAdministrator 07/18/03 12:39 PM
. * Antidepressants in the Treatment of IBS and Other Functional GI Disorders HeatherAdministrator 07/18/03 12:20 PM
. * Use of Antidepressants in the Treatment of IBS? HeatherAdministrator 07/14/03 03:58 PM
. * Combined use of SSRIs and NSAIDs increases the risk of GI adverse effects HeatherAdministrator 07/14/03 03:15 PM

Extra information
0 registered and 7 anonymous users are browsing this forum.

Moderator:  Heather 



Permissions
You cannot post until you login
You cannot reply until you login
HTML is enabled
UBBCode is enabled

Thread views: 349113

Jump to

| Privacy statement Help for IBS Home

*
UBB.threads™ 6.2


Shop For IBS Here!